Biome Delivers First Profit and Strong Growth in FY25

Biome Australia Limited (ASX: BIO) has reported a landmark year in FY25, achieving its first net profit after tax of AU$214,656 alongside record sales revenue of AU$18.4 million, up 41.6% from FY24. The company also posted a sixth consecutive quarter of positive EBITDA, reaching AU$931k for the year, while gross profit climbed to AU$11.25 million with margins improving to 61.1%. The June quarter was a standout, generating over AU$5 million in sales, including a record AU$2.1 million month. Biome’s Activated Probiotics brand secured the number two position in community pharmacy probiotic revenue, with domestic sell-through rising more than 50%. International expansion was equally strong, with sales of AU$1.5 million, representing 69% growth, driven by transformative partnerships across Canada, Ireland, the UK, and New Zealand. The launch of Activated Therapeutics, seven new products, and the registration of its proprietary probiotic strain BMB18 further strengthened innovation. Entering FY26 with an AU$20 million run rate, Biome is firmly on track to achieve its Vision 27 growth targets.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com